We found that the expression levels of RUNX2, DSPP, and OPN were significantly higher in the CGF + LPS + OM group compared with the LPS + OM group, confirming the controlling effect of CGF on LPS-treated DPSCs. The gene discussed is RUNX2; the disease is ocular melanoma.